The U.S. Food and Drug Administration (FDA) reported on Friday that there is a risk of heart inflammation following Novavax’s coronavirus vaccine. That’s despite the company’s data showing that its vaccine can improve people’s resistance to the new coronavirus. The FDA warns that the risk of heart disease from the Novavax Covid-19 vaccine is higher than other vaccines. Novavax was sold off by investors in midday trading on Friday, with its shares tumbling more than 20%. Shares of Novavax, down 86% from their February 2021 record, have also far underperformed other vaccine makers, with Moderna down about 26% over the same period as the market for a coronavirus vaccine is fiercely competitive and demand slumps. Between December 27, 2020, and September 27, 2021, Novavax conducted the trial with nearly 30,000 participants. The study found that its new crown vaccine is 90.4% effective in adults. But in the more than 20 days after vaccination, five patients with myocarditis and pericarditis were reported. The data comes ahead of the FDA’s June 7 meeting to decide whether to approve Novavax’s Covid-19 vaccine for emergency use authorization. The FDA said it has requested Nova .
[related_posts_by_tax taxonomies=”post_tag”]
The post The US FDA warns that a new crown vaccine has a high risk of heart disease: its stock price fell more than 20% appeared first on Gamingsym.